RxDoctor Payments Data

Sherif Costandi, MD

Interventional Pain Management · Cleveland, OHNPI 1811284458

Payments from drug & device makers

$862,398in general payments, 2019–2025

Across 319 payments — averaging $2703.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • MML US, Inc.$413K
  • Vertos Medical, Inc.$222K
  • Medtronic$156K
  • Saluda Medical Americas, Inc.$47K
  • Stryker$23K
  • Boston Scientific$565
  • plus $2K from 9 others
$1,341in research payments, 2019–2025

Across 8 payments — averaging $167.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Vertos Medical, Inc.$814
  • Saluda Medical Americas, Inc.$527

What the payments were for

  • Grants$751%
  • Travel & lodging$1,05221%
  • Food & beverage$3,91678%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few interventional pain management providers in Ohioto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$61,080
Medicare patients
191
Services billed
637

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gabapentin106$903
Tizanidine Hcl28$296
Pregabalin19$220
Cyclobenzaprine Hcl15$148
Meloxicam17$70

Paid to pharmacies, not to this prescriber.

Other interventional pain management in Cleveland

Where these figures come from

Is this you, or does something look wrong? →